SCHEMBL6076305

SCHEMBL6076305

[CH]1CCCCC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20590761 0.93
SCHEMBL9248 0.77
SCHEMBL1985537 0.60
SCHEMBL20411638 0.59
SCHEMBL20411674 0.59
SCHEMBL28079941 0.59
SCHEMBL20411652 0.59
SCHEMBL65257 0.59
SCHEMBL20411704 0.59
SCHEMBL20411669 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7081460-B2 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2006-07-25 US claimed
EP-1389205-B1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS ORTHO MCNEIL PHARMACEUTICAL RE (US) 2005-12-21 EP claimed
EP-1389205-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS Ortho-McNeil Pharmaceutical Research Inc. (US) 2004-02-18 EP claimed
US-20030186967-A1 Acylresorcinol derivatives are selective vitronectin receptor inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2003-10-02 US claimed
US-20030139398-A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-07-24 US claimed
WO-2002081467-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO claimed
WO-1999052879-A1 ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-10-21 WO claimed
WO-2024054926-A1 KRAS G12D INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-14 WO disclosed
CN-117222625-A Substituted pyridazinones, salts or N-oxides thereof and their use as herbicidal agents 拜耳公司 2023-12-12 CN disclosed
CN-117043140-A Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidal active substances 拜耳公司 2023-11-10 CN disclosed
CN-110799511-B Herbicidal 3-phenylisoxazoline-5-carboxamides of tetrahydro-and dihydrofurancarboxamides 拜耳公司 2023-09-01 CN disclosed
CN-110799511-A Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro-and dihydrofurancarboxamides 拜耳公司 2020-02-14 CN disclosed
US-20190337893-A1 ANTIBIOTIC SENSITIVITY-RESTORING AND PHOTOSENSITIVE AGENTS NEW MEXICO TECH UNIV RESEARCH PARK CORPORATION (US) 2019-11-07 US disclosed
WO-2013167963-A1 BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS PURDUE PHARMA L.P. (US) 2013-11-14 WO disclosed
WO-2013084060-A1 QUATERNIZED BUPRENORPHINE ANALOGS PURDUE PHARMA L.P. (US) 2013-06-13 WO disclosed
US-7081460-B2 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2006-07-25 US disclosed
EP-1389205-B1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS ORTHO MCNEIL PHARMACEUTICAL RE (US) 2005-12-21 EP disclosed
EP-1389205-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS Ortho-McNeil Pharmaceutical Research Inc. (US) 2004-02-18 EP disclosed
US-20030139398-A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-07-24 US disclosed
WO-2002081467-A1 QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO disclosed